Princeton-based biosimulation company Certara’s initial public offering earned it $336.5 million in gross proceeds, after the company sold an upsized 29 million shares of common stock at $23 per share.
The initial filings had put the IPO at $100 million, with some reports saying it could be worth up to $500 million. The company had planned to sell 24.4 million shares in a range of $19-22 per share, so the actual IPO exceeded both estimates.
Shares began trading Friday under the symbol “CERT.”
